Abiraterone and Increased Survival in Metastatic Prostate Cancer

20114,368 citationsJournal Articlebronze Open Access

Authors

Johann S. de Bono · Institute of Cancer Research

Christopher J. Logothetis · The University of Texas MD Anderson Cancer Center

Arturo Molina · Los Angeles City College

Karim Fizazi · Institut Gustave Roussy

Scott North · Cancer Institute (WIA)

Luis Chu · Hematology Oncology Consultants

Kim N.

Abstract

The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Radiopharmaceutical Chemistry and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 21, pp. 1995-2005

DOI: 10.1056/nejmoa1014618

Field-Weighted Citation Impact: 312.43